Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...